(3,4-dioxocyclobuten-1-yl)chromene, indene, and...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 311/58 (2006.01) A61K 31/135 (2006.01) A61K 31/275 (2006.01) A61K 31/33 (2006.01) C07C 225/20 (2006.01) C07C 255/56 (2006.01) C07D 405/04 (2006.01) C07D 407/04 (2006.01) C07D 409/04 (2006.01) C07D 413/04 (2006.01)

Patent

CA 2193367

This invention relates to novel 4-(3,4-dioxocyclobuten-1-yl)chromenes and dihydronaphthalenones and 3-(3,4-dioxocyclobuten-1-yl)indenes and salts thereof having smooth muscle relaxing activity, to their use in the treatment of hypertension as well as for treatment of peripheral vascular disease, congestive heart failure, disorders involving excessive smooth muscle contraction of the urinary tract such as incontinence or of the gastrointestinal tract such as irritable bowel syndrome, asthma, and hair loss and to pharmaceutical compositions containing an invention compound. The present invention discloses compounds represented by formula (I), wherein R1 and R2, independent from each other, are selected from the following: C1-6 perfluoroalkoxy, C1-6 perfluoroalkyl, C1-6 alkyl, C1-6 alkoxy, hydroxyl, C1-6 alkoxycarbonyl, nitro, cyano, halogen, C1-6 alkylsulfonamido, C1-6 perfluoroalkylsulfonamido, amino, C1-6 acylamino, C1-6 perfluoroacylamino, mono or di-C 1-12 alkylamino, C1-6 alkylsulfonyl, C6-10 arylsulfonyl, carboxyl, C1-12 mono or di-alkylaminocarbonyl, or hydrogen; a and b together form an -O- linkage, C=O, or a direct bond; R3 and R4, independent from each other, are H or C1-6 alkyl, optionally substituted by fluorine; R5 is amino or C1-12 mono alkylamine; R6 is H, C1-6 perfluoroalkyl, C1-6 alkyl, C6-10 aryl, or mono or bicyclic heteroaryl containing 1-3 heteroatoms selected from N, O, or S.

L'invention concerne de nouveaux 4-(3,4-dioxocyclobutène-1-yl)chromènes et dihydronaphthalénones et 3-(3,4-dioxocyclobutène-1-yl)indènes, ainsi que leurs sels, présentant une efficacité de relâchement des muscles lisses, leur utilisation dans le traitement de l'hypertension, ainsi que dans le traitement de maladies vascularres périphériques, de la défaillance cardiaque oedémateuse, de maladies impliquant une contraction excessive des muscles lisses des voies urinaires, telles que l'incontinence, ou des voies gastrointestinales, telles que la colopathie fonctionnelle, de l'asthme et de la perte des cheveux, ainsi que des compositions pharmaceutiques contenant les composés représentés par la formule (I) dans laquelle: R¿1? et R¿2?, indépendant l'un de l'autre, sont sélectionnés à partir de: perfluoroalcoxy C¿1-6?, perfluoroalkyle C¿1-6?, alkyle C¿1-6?, alcoxy C¿1-6?, hydroxyle, alcoxycarbonyle C¿1-6?,nitro, cyano, halogène, alkylsulfonamido C¿1-6?, perfluoroalkylsulfonamido C¿1-6?, amino, acylamino C¿1-6? perfluoroacylamino C¿1-6?, mono ou di-alkylamino C¿1-12?, alkylsulfonyle C¿1-6?, arylsulfonyle C¿6-10?, carboxyle, mono ou di-alkylaminocarbonyle C¿1-12? ou hydrogène; a et b constituent ensemble une liaison -O-, C=O ou une liaison directe; R¿3? et R¿4?, indépendant l'un de l'autre, représentent H ou alkyle C¿1-6?, éventuellement substitué par fluor; R¿5? représente amino ou mono alkylamine C¿1-12?; R¿6? représente H, perfluoroalkyle C¿1-6?, aryle C¿6-10? ou hétéroaryle mono ou bicyclique contenant 1-3 hétéroatomes sélectionnés à partir de N, O ou S.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

(3,4-dioxocyclobuten-1-yl)chromene, indene, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with (3,4-dioxocyclobuten-1-yl)chromene, indene, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (3,4-dioxocyclobuten-1-yl)chromene, indene, and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1689496

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.